Regeneron won FDA approval for the first gene therapy to restore hearing in deaf children, will offer for free

Regeneron received FDA approval for a gene therapy targeting inherited deafness, a meaningful regulatory milestone for its biotech pipeline. The approval supports the company’s innovation narrative and could broaden future revenue opportunities in a high-need therapeutic area. The news is likely positive for Regeneron shares and supportive for the broader gene therapy subsector.

Analysis

Regeneron received FDA approval for a gene therapy targeting inherited deafness, a meaningful regulatory milestone for its biotech pipeline. The approval supports the company’s innovation narrative and could broaden future revenue opportunities in a high-need therapeutic area. The news is likely positive for Regeneron shares and supportive for the broader gene therapy subsector.